Lava Therapeutics Nv (LVTX)

$1.5158

Market is closed - opens 8 PM, 01 Dec 2023

Insights on Lava Therapeutics Nv

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 5.13M → 53.0K (in $), with an average decrease of 99.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -14.99M → -8.83M (in $), with an average increase of 30.9% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 76.2% return, outperforming this stock by 153.7%

Performance

  • $1.48
    $1.52
    $1.52
    downward going graph

    2.57%

    Downside

    Day's Volatility :2.57%

    Upside

    0.0%

    downward going graph
  • $1.13
    $7.38
    $1.52
    downward going graph

    25.66%

    Downside

    52 Weeks Volatility :84.69%

    Upside

    79.4%

    downward going graph

Returns

PeriodLava Therapeutics NvSector (Health Care)Index (Russel 2000)
3 Months
-14.84%
-1.7%
0.0%
6 Months
-20.22%
2.1%
0.0%
1 Year
-77.54%
-5.8%
-6.0%
3 Years
-89.4%
18.7%
-3.7%

Highlights

Market Capitalization
39.7M
Book Value
$2.08
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.92
Wall Street Target Price
6.8
Profit Margin
0.0%
Operating Margin TTM
-20239.62%
Return On Assets TTM
-23.62%
Return On Equity TTM
-68.44%
Revenue TTM
9.1M
Revenue Per Share TTM
0.34
Quarterly Revenue Growth YOY
-99.7%
Gross Profit TTM
-20.7M
EBITDA
-48.7M
Diluted Eps TTM
-1.92
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.8
EPS Estimate Next Year
-1.79
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Lava Therapeutics Nv(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 348.61%

Current $1.52
Target $6.80

Technicals Summary

Sell

Neutral

Buy

Lava Therapeutics Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lava Therapeutics Nv
Lava Therapeutics Nv
28.46%
-20.22%
-77.54%
-89.4%
-89.4%
Moderna, Inc.
Moderna, Inc.
1.97%
-39.54%
-57.19%
-44.9%
317.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.11%
12.67%
8.22%
60.25%
115.31%
Novo Nordisk A/s
Novo Nordisk A/s
4.26%
28.93%
61.48%
201.7%
342.4%
Seagen, Inc.
Seagen, Inc.
-0.54%
9.52%
76.18%
20.18%
233.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.93%
9.64%
10.62%
54.06%
92.15%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lava Therapeutics Nv
Lava Therapeutics Nv
0.25
NA
NA
-1.8
-0.68
-0.24
0.0
2.08
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lava Therapeutics Nv
Lava Therapeutics Nv
Buy
$39.7M
-89.4%
0.25
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
317.74%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
115.31%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
342.4%
43.04
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
233.4%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
92.15%
26.52
35.94%

Company Information

Organization
Lava Therapeutics Nv
Employees
69
CEO
Mr. Stephen Allen Hurly M.B.A., M.Sc.
Industry
Healthcare

FAQs